AgeX Therapeutics (AgeX Therapeutics) Total Inventories : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is AgeX Therapeutics Total Inventories?

AgeX Therapeutics's total inventories for the quarter that ended in Dec. 2023 was $0.00 Mil. AgeX Therapeutics's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. AgeX Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-5.66.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. AgeX Therapeutics's Days Inventory for the three months ended in Dec. 2023 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. AgeX Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.

AgeX Therapeutics Total Inventories Historical Data

The historical data trend for AgeX Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AgeX Therapeutics Total Inventories Chart

AgeX Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

AgeX Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

AgeX Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

AgeX Therapeutics (AMEX:AGE) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

AgeX Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.345	+	0.75 * 0.057	+	0.5 * 0	-	6.607
-	0	-	-0.111)	/	1.07908
=	-5.66

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

AgeX Therapeutics's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	0	/	0.022	*	365 / 4
	=	0.00

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

AgeX Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	0.022	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

AgeX Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0	/	0.077
	=	0.00

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

AgeX Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of AgeX Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

AgeX Therapeutics (AgeX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AgeX Therapeutics Inc (AMEX:AGE) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

0X4:Germany 0X4:Germany

Address

1101 Marina Village Parkway, Suite 201, Alameda, CA, USA, 94501

Website

https://www.agexinc.com

AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develops medicines designed to address some of the unsolved problems in aging. Its PureStem-derived cell-based therapeutic candidates in development are AGEX-VASC1, AGEX-BAT1 and AGEX-iTR1547.

Executives

Jean-christophe Renondin	director	505 PARK AVENUE 14TH FLOOR, NEW YORK NY 10022
Juvenescence Us Corp.	director, 10 percent owner	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Joanne M. Hackett	director	C/O AGEX THERAPEUTICS, INC.,, 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94708
Park Andrea Eun Jae	officer: Chief Financial Officer	C/O AGEX THERAPEUTICS, INC., 965 ATLANTIC AVE., SUITE 101, ALAMEDA CA 94501
Michael H May	director	965 ATLANTIC AVENUE, SUITE 101, ALAMEDA CA 94501
Michael D West	director, officer: Chief Executive Officer	AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501
Michael H. Mulroy	director	1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Russell Skibsted	officer: Chief Financial Officer	15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Judith Segall	officer: Corporate Secretary	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Hal Sternberg	officer: Vice President-Research	935 PARDEE STREET, BERKELEY CA 94710
Annalisa Jenkins	director	C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
John F Mauldin	director	3204 BEVERLY DRIVE, DALLAS TX 75205
Gregory Bailey	director	4 A CHESHAM STREET, LONDON X0 SW1X8DT
Juvenescence Ltd	10 percent owner	1ST FLOOR, VIKING HOUSE, ST PAULS SQUARE, RAMSEY Y8 IM8 1GB
Nafees Naseer Malik	officer: Chief Operating Officer	C/O AGEX THERAPEUTICS, INC., 1010 ATLANTIC AVE, STE 102, ALAMEDA CA 94501